Shares of Hologic, Inc. (NASDAQ:HOLX) have received an average rating of “Buy” from the sixteen analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $48.00.
A number of equities analysts have recently issued reports on the company. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Tuesday. Evercore ISI assumed coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $50.00 price target on shares of Hologic in a research report on Thursday, February 1st. Finally, Stifel Nicolaus downgraded Hologic from a “buy” rating to a “hold” rating and dropped their price target for the stock from $45.00 to $42.00 in a research report on Friday.
In related news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.88% of the company’s stock.
Hologic (NASDAQ HOLX) traded up $0.29 on Friday, hitting $38.04. The stock had a trading volume of 4,473,200 shares, compared to its average volume of 2,927,948. Hologic has a fifty-two week low of $35.33 and a fifty-two week high of $46.80. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. The company has a market cap of $10,438.97, a P/E ratio of 10.04, a price-to-earnings-growth ratio of 1.71 and a beta of 0.77.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.05. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The business had revenue of $791.10 million for the quarter, compared to the consensus estimate of $785.80 million. During the same quarter in the prior year, the company earned $0.52 EPS. The business’s revenue was up 7.7% compared to the same quarter last year. equities analysts forecast that Hologic will post 2.25 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Hologic, Inc. (HOLX) Receives $48.36 Consensus PT from Analysts” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://sportsperspectives.com/2018/02/13/hologic-inc-holx-receives-48-36-consensus-pt-from-analysts.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.